| Jun 10 |
Verastem: Market Overreaction Creates A Dip Buying Opportunity
|
| Jun 6 |
7 F-Rated Stocks to Avoid at All Costs in June
|
| May 30 |
Russell 3000: Inovio, Ocugen among healthcare additions; Assertio, Ginkgo Bioworks among deletions
|
| May 26 |
Verastem: A Shocking Drop On 'Positive' Data (Maintain Buy)
|
| May 26 |
Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade
|
| May 24 |
Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data
|
| May 24 |
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
|
| May 24 |
Sector Update: Health Care Stocks Advance Pre-Bell Friday
|
| May 24 |
ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success
|
| May 24 |
Verastem whipsaws after updates for cancer drug combo
|
